Q-omics provides the consensus-scored MIR4420 profile across patient tissues and cancer cell-line models. MIR4420 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in THYM. Among the 18 cancer types available for tumor–normal comparison, MIR4420 is differentially expressed in 5, with the highest sampling consensus in KIRC. Additionally, MIR4420 RNA expression shows 13,938 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight THYM, KIRC, and LSCC as cancer lineages where MIR4420 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR4420 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR4420 survival associations across molecular data types. MIR4420 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR4420 RNA expression–survival associations across cancer types. High MIR4420 expression shows unfavorable associations in THYM, UVM, KIRC and UCS, but favorable associations in LUAD and BRCA. The THYM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify THYM as the clearest survival context for MIR4420 RNA expression.
This table summarizes MIR4420 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR4420. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR4420 shows lower tumor expression in LUSC, LUAD and LIHC and higher tumor expression in KIRC and STAD. The KIRC box plot shows higher MIR4420 RNA expression in tumor versus normal tissue (log2 FC = +0.517, t-test p < 0.001).
This table shows molecular features associated with MIR4420 in patient tissues and cancer cell lines. In patient samples, MIR4420 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
